Letter to the Editor

We read with interest the article by Boeters DM et al. \[[@CR1]\]. We would like to clarify the significant findings and suggest further research needed to validate the novel conclusion. In ACPA-negative patients, 1 sustained DMARD-free remission (SDFR) occurred over 5 years follow-up in 17 (6%) with baseline low (\< 30) MBDA score vs approximately 50% remissions in both moderate (30--44) and high (\> 44) MBDA score patients (\[[@CR1]\], Fig. 1). All ACPA-*positive* RA patients had low percentages of SDFR and *no* difference was found by baseline MBDA score category \[[@CR1]\]. Percentages of 3 MBDA categories did *not* differ (*p* = 0.470) between the ACPA-positive and ACPA-negative groups \[[@CR1]\].

SDFR was recently reported by ACPA-negative vs ACPA-positive patients in the *total* Leiden early arthritis cohort (1993--2016; *n* = 1296) \[[@CR2]\], from which the Boeters et al. study \[[@CR1]\] was the most recent inclusion subgroup (2011--2016). In the total inclusion period (1993--2011), SDFR occurred between 5 and 15% in ACPA-positive RA vs 40 to 50% in the ACPA-negative RA \[[@CR2]\], as in Boeters et al. \[[@CR1]\].

Unexpectedly, in multivariate analyses (\[[@CR1]\], Table 2), the 95 ACPA-negative RA patients with high (\> 44) baseline scores had *greater* DMARD-free remission than the 17 reference patients with low (\< 30) MBDA scores (*p* = 0.041). If MBDA were truly a marker of disease activity, one might expect low rather than high MBDA to predict SDFR. Alternatively, if ACPA-negative RA does consist of subgroups \[[@CR1]\], its documentation will require further serological study in separate cohorts \[[@CR2], [@CR3]\] or search for genetic markers \[[@CR3]\]. Confounding variables should be excluded, possibly clinical features related to age at onset, which was found to be a significant (*p* = 0.036) predictor of SDFR (\[[@CR1]\], Table 2) and other disease variables not studied. Is it conceivable that this anomaly \[[@CR1]\] is due to chance occurrence in a small sample size study leading to an incorrect conclusion, especially when borderline (*p* = 0.041) statistical correlation is found \[[@CR1]\]?

A critical review of the value of multibiomarker disease activity score to predict remission in RA was recently published \[[@CR4]\]. The challenging question is whether or not baseline MBDA (or serological markers) are being overinterpreted or overstated with respect to outcomes (or disease subgroups) was critically analyzed \[[@CR4]\].
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